0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Hypertension KOL Interview - US #1

  • PDF Icon

    Newsletter

  • 13 Pages
  • June 2025
  • Region: United States
  • Citeline
  • ID: 5642904
This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1-5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Adempas, Letairis, Opsumit, Orenitram, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

This website uses cookies to ensure you get the best experience. Learn more